Our proprietary Self-Diversifying Antibody Library or SDALibTM platform utilizes a yeast triple-mode system consisting of in-yeast antibody diversification, yeast cell surface presentation and secretion. Abzyme’s in-yeast antibody diversification and FACS selection approaches directly mimic mammalian antibody affinity maturation processes.
Abzyme’s in vivo diversification technology is based on the scientific understanding of DNA hypermutation, protein expression and secretion mechanisms in yeast. Unique to Abzyme is our patent-pending eukaryotic-based in vitro antibody discovery/optimization triple-mode platform with proprietary self-diversifying libraries (N-terminal and C-terminal camelid VHH libraries), rapid target-directed antibody maturation and FACS-based single cell sorting approach used to identify diagnostically and therapeutically relevant antibodies. The platform comprises all aspects of antibody discovery and development, from antibody library design, antibody maturation, antibody expression to bio-manufacturing. Abzyme yeast strains have been extensively engineered to enhance antibody maturation via hypermutation and to optimize antibody expression and transport through the secretory pathway for cell surface presentation and secretion into the culture media. Antibody clones are selected by a multi-step approach including FACS to identify antibodies with desired attributes.